Obesity, Overweight
Conditions
Brief summary
An observational, multicenter, national study with retrospective real-life data collection on the combined treatment of sibutramine and topiramate (off-label use) for the treatment of overweight with comorbidity(ies) or obesity. Data from all adult patients, of both sexes, for whom combination treatment with sibutramine and topiramate, both at any dose/dosage, were prescribed between the year 2011 and the beginning of the study will be included in the study.
Interventions
OTHERSource document data collection
Data from all adult patients, of both sexes, for whom combination treatment with sibutramine and topiramate, both at any dose/dosage, were prescribed between the year 2011 and the beginning of the study will be colected in the study.
Sponsors
Eurofarma Laboratorios S.A.
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Adult patients * Both sexes * Diagnose of overweight with comorbidity(ies) or obesity * Treatment use of sibutramine combined with topiramate * Treatment prescription between 2011 and the beginning of the study
Exclusion criteria
* Use of topiramate for other condition besides overweight with comorbidity(ies) or obesity * Individual use of one of the medications (sibutramine or topiramate)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The percentage of patients who achieved a weight loss greater than 5% | 20 years | Identification of the percentage of patients who achieved a weight loss greater than 5% in relation to the initial body weight. |
Countries
Brazil
Outcome results
None listed